北京上海深圳杭州广州昆明天津成都宁波福州西安南京南宁济南重庆苏州长沙太原武汉贵阳乌鲁木齐郑州石家庄合肥香港巴黎马德里硅谷斯德哥尔摩纽约 BEIJING|SHANGHAI|SHENZHEN|HANGZHOU|GUANGZHOU|KUNMING|TIANJIN|CHENGDU|NINGBO|FUZHOU|XI'AN|NANJING|NANNING|JINAN|CHONGQING|SUZHOU|CHANGSHA|TAIYUAN|WUHAN|GUIYANG|URUMQI|ZHENGZHOUI|SHIJIAZHUANG|HEFEI|HONGKONG|PARIS|MADRID|SILICON VALLEY|STOCKHOLM|NEWYORK 中国上海市北京西路 968 号嘉地中心 27 层 邮编：200041 27/F, Garden Square, 968 West Beijing Road, Shanghai 200041, China 电话/Tel: +86 21 52341668 传真/Fax: +86 21 52433323 网址/Website:http://www.grandall.com.cn 关于上海雪 ...

| 证券代码：300511 | 证券简称：雪榕生物 公告编号：2024-046 | | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | 上海雪榕生物科技股份有限公司 一、主要财务数据概况 截至 2023 年 12 月 31 日，公司经审计合并口径的总资产为 460,216.68 万元， 归属于上市公司股东的净资产为 155,452.96 万元，借款余额为 154,737.86 万元。 截至 2024 年 5 月 17 日，公司借款余额为 207,508.67 万元，较 2023 年末增加 52,770.81 万元，累计新增借款占公司 2023 年末净资产比例为 33.95%。 二、新增借款的分类披露 截至 2024 年 5 月 17 日，公司新增借款（未经审计）分类明细如下： | 借款类别 | 累计新增借款金额 | 新增借款占 2023 年末 | | --- | --- | --- | | | （万元） | 净资产比例（%） | | 银行贷款 | 48,245.82 | 31.04 | | 融资租赁 | 4,525.00 | 2.91 | | 合计 | 52,770.82 | ...

2023年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有出现否决议案的情形。 | 证券代码：300511 | 证券简称：雪榕生物 | 公告编号：2024-045 | | --- | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | | 上海雪榕生物科技股份有限公司 1、会议召集人：公司董事会 2、会议主持人：董事长杨勇萍先生 3、会议召开方式：本次股东大会采取现场表决与网络投票相结合的方式 4、会议召开的日期、时间 （1）现场会议召开时间：2024 年 5 月 17 日 14:30； 2、本次股东大会不涉及变更前次股东大会决议。 3、本次股东大会以现场及网络投票相结合的方式召开。 4、为尊重中小投资者利益，提高中小投资者对公司股东大会决议事项的参 与度，本次股东大会对审议影响中小投资者利益的重大事项时进行单独计票，中 小投资者是指除上市公司董事、监事、高级管理人员以及单独或者合计持有公司 5%以上股份的股东以外的其他股东。 一、会议召开情况 （2）网络投票时间：2024 年 ...

| 证券代码：300511 | 证券简称：雪榕生物 公告编号：2024-044 | | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | 上海雪榕生物科技股份有限公司 关于预计触发转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、证券代码：300511 证券简称：雪榕生物 2、债券代码：123056 债券简称：雪榕转债 3、转股价格：4.20元/股 4、转股期限：2021年1月4日至2026年6月23日 5、根据上海雪榕生物科技股份有限公司（以下简称"公司"）《创业板公开发 行可转换公司债券募集说明书》（以下简称"《募集说明书》"）的规定：在本次发 行的可转换公司债券存续期间，当公司股票在任意连续三十个交易日中至少有十五 个交易日的收盘价低于当期转股价格的85%时，公司董事会有权提出转股价格向下 修正方案并提交公司股东大会表决。 自2024年4月15日至2024年4月26日，公司股票已有十个交易日的收盘价低于当 期转股价格的85%（即3.57元/股），预计后续将可能触发"雪榕转债"转 ...

Financial Performance - In 2023, the company achieved operating revenue of CNY 2,565.14 million, a year-on-year increase of 10.55%, while the net profit attributable to shareholders was a loss of CNY 188.06 million[5]. - The company's operating revenue for 2023 reached ¥2,565,144,194.86, representing a 10.55% increase compared to ¥2,320,432,033.82 in 2022[40]. - The net profit attributable to shareholders for 2023 was ¥188,062,576.34, a decrease of 34.52% from ¥287,226,615.66 in 2022[40]. - The net cash flow from operating activities was ¥357,835,977.19, showing a slight decrease of 2.53% from ¥367,133,291.06 in 2022[40]. - The total assets at the end of 2023 amounted to ¥4,602,166,751.34, an increase of 13.02% from ¥4,072,032,070.00 at the end of 2022[40]. - The total revenue for the year 2023 was approximately RMB 2.35 billion, representing a year-on-year increase of 13.47% compared to RMB 2.07 billion in 2022[79]. - The company reported a significant drop in net profit after deducting non-recurring gains and losses, with a total of ¥194,869,834.70 in 2023 compared to ¥310,590,426.00 in 2022, a decrease of 37.26%[40]. Market and Competition - The competitive landscape in the edible mushroom industry has intensified, leading to a downward pressure on product prices due to increased production capacity from competitors[10]. - The company anticipates that the increased supply of edible mushrooms may lead to short-term imbalances in supply and demand, affecting sales prices in the near future[10]. - The company plans to enhance its marketing efforts and improve product quality to maintain market share amid rising competition and price pressures[13]. - The edible mushroom industry in China has seen a decline in the number of factory production enterprises, decreasing from 417 in 2019 to 337 by the end of 2021, a reduction of nearly 20%[52]. - The company is expanding its market presence in Southeast Asia by establishing trade companies in Vietnam and Malaysia[72]. Production and Capacity - The company has a daily production capacity of 1,710 tons of edible mushrooms, with 1,275 tons of that being enoki mushrooms, ranking first in the country[53]. - The company is focusing on expanding production capacity in response to market demand, with several projects, including a 120,000-ton modern agricultural industrial park in Guangxi and a 53,000-ton enoki mushroom project in Fujian, coming online[52]. - The company plans to expand its production capacity and operational scale while maintaining key production indicators for edible mushrooms, which poses a risk to management efficiency and requires a robust management system[20]. Financial Management and Risks - The company is facing risks related to raw material price fluctuations, which could impact production costs and overall profitability if not managed effectively[14]. - The company's liquidity position is under scrutiny, with current liabilities exceeding current assets by CNY 1.346 billion, but it maintains the ability to secure financing through established credit lines[11]. - The company has acknowledged accounting errors in previous years, leading to restatements of financial data for 2020-2022, as mandated by regulatory authorities[40]. - The company has implemented a unified procurement model for raw materials, reducing reliance on suppliers and optimizing costs[63]. Research and Development - The company holds 59 patents, including 21 invention patents, and has been recognized for its technological advancements in mushroom production[68]. - The company is actively involved in research and development, being selected as a key laboratory for edible mushroom strain research by the Ministry of Agriculture and Rural Affairs[68]. - The company aims to enhance the activity of mushroom strains through its ongoing R&D project, which is expected to strengthen its core competitiveness in the market[87]. - The total R&D investment for 2023 was CNY 8,139,486.19, maintaining a ratio of 0.32% of operating revenue, consistent with 2022[91]. Governance and Compliance - The company has established a comprehensive governance structure in compliance with relevant laws and regulations, ensuring independent operations from its controlling shareholders[120]. - The board of directors consists of 7 members, including 3 independent directors, meeting legal and regulatory requirements[121]. - The company has not provided guarantees for its controlling shareholders and has maintained independence in its operations[120]. - The company has committed to timely and accurate information disclosure, ensuring equal access for all shareholders[124]. Employee Management - The total number of employees at the end of the reporting period was 2,513, with 198 in the parent company and 2,315 in major subsidiaries[155]. - The employee composition includes 1,612 production personnel, 99 sales personnel, 406 technical personnel, 66 financial personnel, and 330 administrative personnel[155]. - The company has established a dual-channel talent development system focusing on general and elite talent to enhance employee capabilities[159]. - The company emphasizes a fair and competitive salary system based on performance, efficiency, and fairness principles[157]. Environmental and Social Responsibility - The company has invested in poverty alleviation initiatives, building edible mushroom precision poverty alleviation industrial parks in Guizhou and Gansu, contributing to local economic development[184]. - The company continues to prioritize employment for poverty-stricken households, providing training and guidance to enhance labor skills and improve local employment conditions[185]. - The company has implemented a comprehensive environmental management system that meets regulatory requirements, with no reported administrative penalties for environmental issues during the reporting period[182]. Shareholder Engagement - The company held several shareholder meetings in 2023, with participation rates of 29.07% for the first temporary meeting and 25.35% for the annual meeting[128]. - The company has proposed a restricted stock incentive plan during the meeting on August 23, 2023[151]. - The company has committed to not transferring more than 25% of its directly or indirectly held shares during its tenure, with a lock-up period of 12 months following the IPO date[188].

一、担保情况及售后回租赁情况概述 证券代码：300511 证券简称：雪榕生物 公告编号：2024-042 债券代码：123056 债券简称：雪榕转债 上海雪榕生物科技股份有限公司 关于全资子公司开展售后回租赁业务 暨2023年度担保额度预计的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 （一）担保情况概述 上海雪榕生物科技股份有限公司（以下简称"公司"）于2023年7月31日召开了 第四届董事会第五十一次会议和第四届监事会第二十六次会议、于2023年8月23日召 开了2023年第三次临时股东大会，分别审议通过了《关于2023年度担保额度预计的 议案》。为满足公司及子公司生产经营和业务发展需要，确保资金流畅通，公司在 保证规范运营和风险可控的前提下，预计在2023年度为子公司向银行或其他金融机 构申请融资业务时提供总额度不超过人民币21.5亿元（含本数）的担保，其中，公司 为资产负债率低于70%的子公司提供担保额度为17.5亿元人民币（含本数），为资产 负债率高于70%的子公司提供担保额度为4.0亿元人民币（含本数），担保额度有效 期限自公司2023 ...

| 证券代码：300511 | 证券简称：雪榕生物 | 公告编号：2024-038 | | --- | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | | 上海雪榕生物科技股份有限公司 关于召开 2023 年年度股东大会通知的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 上海雪榕生物科技股份有限公司（以下简称"公司"）第五届董事会第九次 会议审议通过了《关于召开 2023 年年度股东大会的议案》，决定于 2024 年 5 月17日召开公司2023年年度股东大会，现将本次股东大会的有关事项通知如下： 一、本次股东大会召开的基本情况 1、股东大会届次：2023 年年度股东大会。 2、股东大会召集人：公司董事会。 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》等规定。 4、会议召开的日期、时间 5、会议的召开方式：本次股东大会采取现场表决与网络投票相结合的方式。 （1）现场投票：股东本人出席现场会议或通过授权委托他人出席现场会议； （2）网络投票：本次股东大会将通 ...

| 证券代码：300511 | 证券简称：雪榕生物 公告编号：2024-034 | | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | 上海雪榕生物科技股份有限公司 关于前期会计差错更正及追溯调整的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 上海雪榕生物科技股份有限公司（以下简称"公司"）于2024年4月25日召开 第五届董事会审计委员会第五次会议、第五届董事会第九次会议和第五届监事会 第七次会议，分别审议通过了《关于前期会计差错更正及追溯调整的议案》，同 意公司根据《企业会计准则第28号——会计政策、会计估计变更和差错更正》《公 开发行证券的公司信息披露编报规则第19号——财务信息的更正及相关披露》等 相关规定和要求，对公司前期会计差错进行更正并追溯调整相关年度的财务数 据。现将具体事项公告如下： 一、前期会计差错更正的原因及内容 （一）前期会计差错更正的原因 公司于2023年12月25日收到中国证券监督管理委员会上海监管局（以下简称 "上海证监局"）印发的《关于对上海雪榕生物科技股份有限公司采取责令改正措 施的决定 ...

Financial Performance - The company's operating revenue for the reporting period was ¥928,810,813.47, a decrease of 6.73% compared to ¥995,800,104.43 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥70,702,210.37, representing a decline of 145.48% from a profit of ¥155,466,147.74 in the previous year[4] - Basic and diluted earnings per share were both -¥0.16, a decrease of 144.44% compared to ¥0.36 in the previous year[5] Cash Flow - The net cash flow from operating activities was ¥51,797,697.21, down 80.88% from ¥270,882,499.62 in the same period last year[5] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,311,699,860.85, a decrease of 5.19% from ¥4,547,783,435.53 at the end of the previous year[5] - The net assets attributable to shareholders were ¥1,900,602,599.20, down 5.78% from ¥2,017,187,114.89 at the end of the previous year[5] - The company's asset-liability ratio was 55.97%, slightly up from 55.89% at the end of the previous year[11] Financial Ratios - The EBITDA interest coverage ratio was 2.38, down from 8.77 in the same period last year[11] Dividends and Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[1] - There were no changes in the controlling shareholder or actual controller during the reporting period[7]

二、财务状况、经营成果和现金流量情况分析 上海雪榕生物科技股份有限公司 2023 年度财务决算报告 根据上海雪榕生物科技股份有限公司截止 2023 年 12 月 31 日的财务状况和 2023 年度的经营成果和现金流量，结合公司实际运营中的具体情况，我们进行 了认真的研究分析，现将公司有关的财务决算情况汇报如下： 一、2023 年公司财务报表审计情况 公司 2023 年财务报表已经安永华明会计师事务所（特殊普通合伙）审计， 出具了安永华明（2024）审字第 70009152_B01 号标准无保留意见审计报告。会 计师的审计意见是：公司财务报表在所有重大方面按照企业会计准则的规定编制， 公允反映了上海雪榕生物科技股份有限公司 2023 年 12 月 31 日的合并及公司财 务状况以及 2023 年度的合并及公司经营成果和现金流量。 （一）资产情况： | 单位：万元 | | --- | | 项目 | 2023 | 年 12 | | 年 2022 12 | 同比增减 | 占总资产比重 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 月 31 日 | ...